本报记者 张悦 曹学平 北京报道近期,医药企业三季报陆续发布。HPV疫苗行业的万泰生物(603392.SH)、沃森生物(300142.SZ)、智飞生物(300122.SZ)前三季度业绩同比均有不同程度的下降。其中,万泰生物2024年前三季度实现营业收入19.48亿元、同比下降60.79%,净利润2.67亿元,同比下降85.25%。沃森生物前三季度公司实现营业收入21.41亿元、同比下降32.19%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.